Unogen Biotechnology

Unogen Biotechnology is a clinical-stage biopharmaceutical company based in Suzhou, China, dedicated to the discovery and development of innovative antibody therapeutics for cancer and immunological disorders. The company utilizes its proprietary Unobody platform to design and engineer high-affinity monoclonal and multi-specific antibodies with optimized pharmacological properties. Its lead candidate, UNG-001, is a humanized anti-CD47 monoclonal antibody currently in clinical trials for hematological and solid tumors. Additionally, Unogen is advancing UNG-002, targeting Claudin 18.2, and a robust pipeline of next-generation biologics. By integrating deep biological insights with advanced engineering, Unogen aims to provide more effective and safer treatment options for patients worldwide.